Active Filter(s):
Details:
EXE-346 is a live biotherapeutic product (LBP) a blend of probiotic bacteria formulated in extremely high potency. The product is currently under development to manage excessive stool frequency in patients who have undergone an ileal pouch-anal anastomosis (IPAA).
Lead Product(s): EXE-346
Therapeutic Area: Gastroenterology Product Name: EXE-346
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 26, 2023
Details:
EXE-346 is an LBP which contains a fixed-proportion of 8 strains of live probiotic bacteria which are intended for oral administration. EXE-346 is intended to decrease this inflammation of the pouch and prevent active disease flare-ups.
Lead Product(s): EXE-346
Therapeutic Area: Immunology Product Name: EXE-346
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 12, 2020
Details:
Italian clinical study finds combined strains of live bacteria reduced diarrhea and lessened progression of symptoms in hospitalized COVID-19 patients.
Lead Product(s): Live Biotherapeutic Product,Hydroxychloroquine Sulphate,Antibiotics
Therapeutic Area: Infections and Infectious Diseases Product Name: SivoBiome
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2020